People · Operator
Named in public records as an officer, director or promoter · active 2012–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Horizon Pharma, Inc. | — | Pharmaceuticals | Series D+ | $308.4M | $5.3B | 2012 |
Ronald W. Pauli at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ronald W. Pauli on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Louis C. Bock | 1 | 7 |
| Jeffrey W. Bird | 1 | 6 |
| Gino W. Santini | 1 | 3 |
| Timothy P. Walbert | 1 | 3 |
| Jean-Francois W. Formela | 1 | 1 |
| Michael W. Grey | 1 | 1 |
| Jeff C. Himawan | 1 | 1 |
| Jeff P. Himawan | 1 | 1 |
| Hubert W. Birner | 1 | 1 |
| Robert P. De Vaere | 1 | 1 |
| Peter W. Johann | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.